Study suggests some Ebola antibodies may be less effective against Bundibugyo virus

Researchers conducted genomic analysis and modeling of the Bundibugyo virus to evaluate how approved and experimental Ebola antibodies interact with its glycoprotein. The study found that the approved antibody Ebanga may have disrupted binding, while MBP134 targets were conserved, and the Inmazeb cocktail showed different binding behavior compared to its individual antibodies. Laboratory tests are necessary to confirm whether these modeling results translate into actual treatment efficacy.

Originally published by gnews